[News] 2023 ASCO Annual Meeting

In the randomised, placebo-controlled, phase 3 DUO-O trial presented by Philipp Harter (Kliniken Essen-Mitte, Essen, Germany), patients with BRCA wild-type advanced ovarian cancer received one cycle of carboplatin and paclitaxel, 1130 of whom were randomly assigned (1:1:1) to carboplatin and paclitaxel (chemotherapy) plus intravenous bevacizumab (15 mg/kg every 3 weeks) and durvalumab placebo followed by maintenance bevacizumab plus durvalumab and olaparib placebos (n=378; group 1); chemotherapy plus bevacizumab and intravenous durvalumab (1120 mg every 3 weeks) followed by maintenance bevacizumab, durvalumab, and olaparib placebo (n=374; group 2); or chemotherapy plus bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab, and oral olaparib (300 mg twice daily; n=378; group 3).